ASH 2018 | Analyzing AML: novel therapies in review

Farhad Ravandi

Farhad Ravandi-Kashani, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, shares key highlights, including trials, future outlooks, and progressions in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video